FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review-Reference-Cited by-同舟云学术

FDA Approved Biologics: Can Etanercept and Ustekinumab be Considered a First-Line Systemic Therapy for Pediatric/Adolescents in Moderate to Severe Psoriasis? A Systematic Review

Published:2020-08-17 Issue: Volume: Page:
ISSN:2168-8184
Container-title:Cureus
language:en
Short-container-title:

Author:

Aslam Nida,Saleem Hajra,Murtazaliev Salikh,Quazi Sohail J,Khan Safeera

Publisher

Cureus, Inc.

Subject

Aerospace Engineering

Reference29 articles.

1. Psoriasis;Boehncke WH;Lancet,2015

2. Efficacy and safety of ustekinumab in adolescents;Kellen R;Pediatric Health Med Ther,2016

3. Management of pediatric plaque psoriasis using biologics;Lansang P;J Am Acad Dermatol,2020

4. Incidence of psoriasis in children: a population-based study;Tollefson MM;J Am Acad Dermatol,2010

5. Pediatric psoriasis comorbidity screening guidelines;Osier E;JAMA Dermatol,2017

Cited by 10 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Current and emerging prospects in the psoriatic treatment;International Immunopharmacology;2023-07

2. Risk of Infection in Children With Psoriasis Receiving Treatment With Ustekinumab, Etanercept, or Methotrexate Before and After Labeling Expansion;JAMA Dermatology;2023-03-01

3. Efficacy and safety of biologics and small molecules for psoriasis in pediatric and geriatric populations. Part I: focus on pediatric patients;Expert Opinion on Drug Safety;2023-01-02

4. Physician-reported Clinical Unmet Needs, Burden and Treatment Patterns of Paediatric Psoriasis Patients: a US and EU Real-world Evidence Study;Acta Dermato-Venereologica;2021-12-22

5. The Cytokine Mediated Molecular Pathophysiology of Psoriasis and Its Clinical Implications;International Journal of Molecular Sciences;2021-11-26